Abstract
Background/Aim: Previous work in rodent models showed that an autologous tissue vaccine is both a safe and effective approach for treating cancer; however, as a translational step, safety must first be evaluated in a more clinically-relevant model. Materials and Methods: An autologous immunotherapy produced from resected tumors, was evaluated in a clinically-relevant canine model to assess safety. Ninety-three dogs with spontaneously occurring tumors received vaccination with inactivated autologous tumor tissue combined with an adjuvant of particulate porcine small intestinal submucosa extracellular matrix (SIS-ECM). Patients were followed to assess the occurrence of adverse events, overall survival, and tumor recurrence and/or metastasis. Results: A small number (12%) of patients experienced limited, mild pyrexia, injection site swelling, or lethargy, all resolving without clinical intervention. Conclusion: Autologous whole cell cancer immunotherapy can be used safely in the canine model of cancer and represents a safe approach for the treatment for cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 1699-1703 |
| Number of pages | 5 |
| Journal | Anticancer Research |
| Volume | 39 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2019 |
Bibliographical note
Publisher Copyright:© 2019 International Institute of Anticancer Research. All rights reserved.
Funding
The Authors thank Alexus Maschinot, Lauren Klein and Meaghan Bolles for all their help with tumor processing; Isabella Raymond for assisting with data analysis; the Technological Incubation Program (TIP) at the University of Connecticut for providing wet and dry labs, offices and co-working spaces in Farmington, Connecticut as well as access to instrumentation, research services and collaboration with scientific experts; and Connecticut Innovations and UConn Innovation Fund for funding this project.
| Funders |
|---|
| UConn Innovation Fund |
| Connecticut Innovations |
| Vehicle Technologies Program |
| Connecticut 06520 Yale University New Haven Connecticut 06520 |
| CCNU-QLPL Innovation Fund |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Autologous vaccine
- Cancer immunotherapy
- Dog
- Model
- Safety
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Safety evaluation of autologous tissue vaccine cancer immunotherapy in a canine model'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver